{"eventGroups":[{"description":"Patients receive oral lenalidomide on days 1-21. Treatment repeats every 28 days for up to 7 courses in the absence of disease progression or unacceptable toxicity. Patients receive pneumococcal polyvalent vaccine intramuscularly (IM) 14 days prior to beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).\n\npneumococcal polyvalent vaccine: Given intramuscularly\n\nlenalidomide: Given orally","id":"EG000","otherNumAffected":1,"otherNumAtRisk":11,"seriousNumAffected":1,"seriousNumAtRisk":11,"title":"Group 1"},{"description":"Patients receive lenalidomide as in group 1. Patients receive pneumococcal polyvalent vaccine IM approximately 45 days after beginning lenalidomide and again in approximately 2 months (after the first dose of the vaccine).\n\npneumococcal polyvalent vaccine: Given intramuscularly\n\nlenalidomide: Given orally","id":"EG001","otherNumAffected":1,"otherNumAtRisk":11,"seriousNumAffected":0,"seriousNumAtRisk":11,"title":"Group 2"}],"frequencyThreshold":"0","otherEvents":[{"organSystem":"Musculoskeletal and connective tissue disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":11,"numEvents":0}],"term":"Lower back pain"},{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":11,"numEvents":0}],"term":"Anemia"},{"organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":11,"numEvents":0}],"term":"Shortness of breath on exertion"},{"organSystem":"Renal and urinary disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Renal insufficiency"},{"organSystem":"Cardiac disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Hypertension"},{"organSystem":"Metabolism and nutrition disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Hyperlipidemia"},{"organSystem":"Respiratory, thoracic and mediastinal disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Cough"},{"organSystem":"Skin and subcutaneous tissue disorders","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":11,"numEvents":0},{"groupId":"EG001","numAffected":1,"numAtRisk":11,"numEvents":1}],"term":"Rash"}],"seriousEvents":[{"organSystem":"Blood and lymphatic system disorders","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":11,"numEvents":1},{"groupId":"EG001","numAffected":0,"numAtRisk":11,"numEvents":0}],"term":"Thrombocytopenia"}]}